Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. 

Biotechnology

Akashi Therapeutics

Akashi Therapeutics' headquarters in Cambridge, MA, United States

Marc B. Blaustein

Ernest D. Bush

Robert Pacifici

Dominic Wells

Francesco Muntoni

Tom Wicka

Merit Cudowitz

Anthony Amato

Jeffrey Chamberlain

John Dyett

Cristina Csimma

Bahaa W. Fam

Benjamin Seckler

The Scientific Advisory Team at Akashi Therapeutics provides expert guidance on research strategies, clinical trial designs, and the development of therapeutic products targeting Duchenne muscular dystrophy and other rare diseases, leveraging their extensive knowledge and experience to ensure scientific rigor and innovation.

Scientific Advisory Team

The Leadership Team at Akashi Therapeutics is responsible for strategic decision-making and guiding the company's vision in the development of innovative therapies for Duchenne muscular dystrophy and other rare diseases. Comprising key executives—including the CEO and Chief Medical and Scientific Officers—this team collaborates to ensure scientific rigor, regulatory compliance, and alignment with the company's mission to deliver impactful treatments to underserved patient populations.

Leadership Team

��

Akashi Therapeutics

Org chart

Board & advisors

Teams

Scientific Advisory Team

Leadership Team

Offices

��������

Akashi Therapeutics

Org chart

Board & advisors

Teams

Scientific Advisory Team

Leadership Team

Offices

Related companies

��